GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

Year in Review 2024 - Hepatobiliary Cancers

Oncology 2024 Year in Review

R. Kim, T. Biachi

Multidisciplinary Approach to Hepatocellular Carcinoma

UCLA Health

G. Choi, B. Yanny, S. Sadeghi, J. Hui

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunot…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

ASCO® GI 2025 Insights: Real-World Experience With Atezo + Bev in Un…

Insights from 2025 ASCO® GI Annual Meeting

M. Abdelrahim

Everything IR in HCC: Conversation With Riad Salem

Nina Niu Sanford

N. Sanford, R. Salem

ASCO® GI 2025 Summary: Key Trial Highlights in Hepatobiliary Cancer …

Insights from 2025 ASCO® GI Annual Meeting

R. Kim, T. Biachi

Updates in Hepatocellular Carcinoma

Michigan Medicine

N. Razumilava

ASCO® GI 2025 Summary: Intermediate HCC and the Management of Liver …

Insights from 2025 ASCO® GI Annual Meeting

M. Reig

Resection, Ablation, and the Emerging Role of Immunotherapy in Early…

The France Foundation

A. Burgoyne

Interventional Treatment of Hepatocellular Carcinoma: Combination of…

Thomas Vogl

Expert Panel on TACE and TARE for HCC: Weighing the Pros and Cons

Integrity CE

M. Pishvaian, R. Salem

Management of Hepatocellular Carcinoma

8th Annual Liver Conference

A. Singal

Guidelines for Assessment and Management for Advanced HCC

The France Foundation

K. Kelley

Choosing the Best HCC Treatment Based on Patient and Disease Stage

Integrity CE

M. Pishvaian, R. Finn, R. Salem, A. Singal

Multidisciplinary Tumor Board Case: Pt With Alcohol-Associated, Chil…

The France Foundation

O. Ahmed, A. A. Pillai, J. Franses

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

H. Babiker

ASCO® GI 2025 Insights: Real-World Outcomes of Durvalumab +/- Tremel…

Insights from 2025 ASCO® GI Annual Meeting

C. Celsa